Cargando…

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations

BACKGROUND: Nail psoriasis is a common clinically significant symptom of psoriasis. However, few studies have focused on the characteristics and course of toenail psoriasis. OBJECTIVE: To investigate the treatment response of toenail psoriasis during a 52-week period of ustekinumab use. METHODS: Pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Seungkeol, Kim, Bo Ri, Kim, Minsu, Youn, Sang Woong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082003/ https://www.ncbi.nlm.nih.gov/pubmed/33935454 http://dx.doi.org/10.5021/ad.2021.33.2.131

Ejemplares similares

Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
por: Choi, Chong Won, et al.
Publicado: (2018)

Docetaxel-Aggravated Psoriasis
por: Yang, Seungkeol, et al.
Publicado: (2019)

Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
por: Choi, Chong Won, et al.
Publicado: (2018)

Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment
por: Kim, Bo Ri, et al.
Publicado: (2018)

Severe Nail Fold Psoriasis Extending from Nail Psoriasis Resolved with Ustekinumab: Suggestion of a Cytokine Overflow Theory in the Nail Unit
por: Byun, Sang Young, et al.
Publicado: (2016)

Adherence to Topical Therapies for the Treatment of Psoriasis: Surveys of Physicians and Patients
por: Choi, Jee Woong, et al.
Publicado: (2017)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Histopathological Findings Are Associated with the Clinical Types of Psoriasis but Not with the Corresponding Lesional Psoriasis Severity Index
por: Kim, Byung Yoon, et al.
Publicado: (2015)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Listeria Meningitis in a Patient With Plaque Psoriasis on Ustekinumab Therapy
por: Roy, Moni, et al.
Publicado: (2022)

The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice
por: Choi, Chong Won, et al.
Publicado: (2017)

Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
por: Kim, Ye Seul, et al.
Publicado: (2016)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
por: Youn, Sang Woong, et al.
Publicado: (2016)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept
por: Choi, Chong Won, et al.
Publicado: (2019)

Both Educational Lectures and Reference Photographs Are Necessary to Improve the Accuracy and Reliability of Psoriasis Area and Severity Index (PASI) Assessment: Results from Korean Nation-Wide PASI Educational Workshop
por: Choi, Chong Won, et al.
Publicado: (2018)

Influence of ustekinumab on body weight of patients with psoriasis: an initial report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2014)

Reduction of Inter-Rater and Intra-Rater Variability in Psoriasis Area and Severity Index Assessment by Photographic Training
por: Youn, Sang Woong, et al.
Publicado: (2015)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Genome-Wide Association Study of Ustekinumab Response in Psoriasis
por: Connell, William T., et al.
Publicado: (2022)

Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab
por: Zhao, Yue, et al.
Publicado: (2014)

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
por: Anzengruber, Florian, et al.
Publicado: (2018)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Predictive Model for Differential Diagnosis of Inflammatory Papular Dermatoses of the Face
por: Kim, Bo Ri, et al.
Publicado: (2020)

Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All?
por: Kim, Bo Ri, et al.
Publicado: (2017)

Bullous pemphigoid during ustekinumab therapy
por: Le Guern, Aurore, et al.
Publicado: (2015)

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
por: Krulig, Eliana, et al.
Publicado: (2010)

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
por: Hermanns-Lê, Trinh, et al.
Publicado: (2012)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Morphological Characteristics of Psoriatic Lesions Affect the Accuracy and Reliability of Severity Assessments: Proposal for New Working Criteria for the Psoriasis Area and Severity Index
por: Choi, Chong Won, et al.
Publicado: (2019)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Idiopathic Sporadic Onychomadesis of Toenails
por: Suchonwanit, Poonkiat, et al.
Publicado: (2016)

Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
por: Avgerinou, Georgia, et al.
Publicado: (2012)

The use of ustekinumab in a patient with severe psoriasis and positive HBV serology()
por: Steglich, Raquel Bissacotti, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k6svoa83ugdjcjeq43j1h60mbn